A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Nektar's recent share price decline comes despite encouraging data for PEGylated irinotecan NKTR-102 in breast cancer and ovarian cancer. The pullback appears to be due to a rebalancing of demand as more conservative biotech investors depart now that the company has declared their intention of proceeding to phase III trials of NKTR-102 without a partner. For the long-term, sales are likely a better strategy than royalties as long as the company is able to manage their debt with a looming repayment deadline in 2012.
The GBMB is not a long-term strategy, so I wouldn't look at Nektar for a real-life buy unless the pullback continued into the single digits.